Calvenza-03 EIV/EHV

Company: Boehringer Ingelheim

Equine Rhinopneumonitis-Influenza Vaccine

Killed Virus

Calvenza-03 EIV/EHV Indications

For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory diseases caused by equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4), and by equine influenza virus types A2 North American and A2 Eurasian.

Administration and Dosage: Shake well before use. Using aseptic technique, inoculate horses intramuscularly with a 2 mL dose. Administer a second 2 mL dose intramuscularly in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks by either the intramuscular or intranasal route.

Precautions

Store at 35-45°F (2-7°C). Protect from freezing. Do not vaccinate within 21 days before slaughter. Use entire contents when first opened. Anaphylactoid reactions may occur following use. Antidote: Epinephrine.

This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies, or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.

Preservative: Gentamicin and thimerosal.

Patents US 6,803,041 and US 7,226,604

For Veterinary Use Only

Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506

U.S. Veterinary License No. 124

CPN: 1028128.5